Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-GLP1R, GSK 716155 Vector   (CAT#: GTVCR-WQ1313MR)

This product GTVCR-WQ1313MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting GLP1R. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Homo sapiens
RefSeq NM_002062.5
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-GLP1R, GSK 716155 Vector (GTVCR-WQ1313MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1728MR IVTScrip™ pT7-VEE-mRNA-Anti-ERBB3, LJM716 Vector Vector LJM716
GTVCR-WQ576MR IVTScrip™ pT7-VEE-mRNA-Anti-ALB, aALB03 Vector Vector aALB03
GTVCR-WQ660MR IVTScrip™ pT7-VEE-mRNA-Anti-CD274, BCD-135 Vector Vector BCD-135
GTVCR-WQ2469MR IVTScrip™ pSP6-VEE-mRNA-Anti-TNFRSF8, SGN-35 Vector Vector SGN-35
GTVCR-WQ1079MR IVTScrip™ pT7-VEE-mRNA-Anti-HA, CT-P22 Vector Vector CT-P22
GTVCR-WQ2234MR IVTScrip™ pSP6-VEE-mRNA-Anti-PDCD1, PF-06801591 Vector Vector PF-06801591
GTVCR-WQ566MR IVTScrip™ pSP6-VEE-mRNA-Anti-VEGFA, AT-001 Vector Vector AT-001
GTVCR-WQ1019MR IVTScrip™ pT7-VEE-mRNA-Anti-CCL2, CNTO 888 Vector Vector CNTO 888
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW